Recombinant
RabMAb

Anti-Orai1 antibody [EPR3394(2)] (ab111960)

Overview

  • Product name
    Anti-Orai1 antibody [EPR3394(2)]
    See all Orai1 primary antibodies
  • Description
    Rabbit monoclonal [EPR3394(2)] to Orai1
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: ICC,IHC-Fr,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide, corresponding to residues from Human Orai1.

  • Positive control
    • Human platelet lysate and Ovary cancer lysate.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab111960 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 35,50 kDa (predicted molecular weight: 33 kDa).
  • Application notes
    Is unsuitable for ICC,IHC-Fr,IHC-P or IP.
  • Target

    • Function
      Ca(2+) release-activated Ca(2+) (CRAC) channel subunit which mediates Ca(2+) influx following depletion of intracellular Ca(2+) stores and channel activation by the Ca(2+) sensor, STIM1. CRAC channels are the main pathway for Ca(2+) influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT.
    • Involvement in disease
      Defects in ORAI1 are the cause of immune dysfunction with T-cell inactivation due to calcium entry defect type 1 (IDTICED1) [MIM:612782]. IDTICED1 is an immune disorder characterized by recurrent infections, impaired T-cell activation and proliferative response, decreased T-cell production of cytokines, and normal lymphocytes counts and serum immunoglobulin levels. In surviving patients ectodermal dysplasia with anhydrosis and non-progressive myopathy may be observed.
    • Sequence similarities
      Belongs to the Orai family.
    • Cellular localization
      Cell membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Calcium release activated calcium channel protein 1 antibody
      • Calcium release activated calcium modulator 1 antibody
      • Calcium release-activated calcium channel protein 1 antibody
      • CRACM 1 antibody
      • CRACM1 antibody
      • CRCM1 antibody
      • CRCM1_HUMAN antibody
      • FLJ14466 antibody
      • Orai 1 antibody
      • ORAI calcium release activated calcium modulator 1 antibody
      • orai1 antibody
      • ORAT1 antibody
      • Protein orai 1 antibody
      • Protein orai-1 antibody
      • TMEM 142A antibody
      • TMEM142A antibody
      • Transmembrane protein 142A antibody
      see all

    Images

    • All lanes : Anti-Orai1 antibody [EPR3394(2)] (ab111960) at 1/1000 dilution

      Lane 1 : Human platelet lysate
      Lane 2 : Human ovary cancer lysate

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 33 kDa

    References

    This product has been referenced in:
    • Zhu M  et al. Store-operated Ca(2+) entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation. J Exp Clin Cancer Res 33:98 (2014). Read more (PubMed: 25433371) »

    See 1 Publication for this product

    Customer reviews and Q&As

    The concentration of lot GR100052 is 0.509 mg/ml.

    Thank you for contacting us and your interest in our products. I am pleased to provide the following immunogen information: In order to aid your research we are happy to provide this information to you. However, this immunogen sequence is propr...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up